Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Iterum Therapeutics plc Director's Dealing 2018

May 29, 2018

34796_dirs_2018-05-29_04b96264-31ce-4c6a-a5ad-4a47419b09fe.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2018-05-24

Reporting Person: Malik Shahzad (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-05-24 Stock Option (Right to Buy) $13.00 A 11241 Acquired 2028-05-23 Ordinary Shares (11241) Direct

Footnotes

F1: Subject to the Reporting Person providing continuous service, the shares subject to this option shall vest on May 24, 2019.